FOR IMMEDIATE RELEASE
June 1, 2016
AbbVie GK
Eisai Co., Ltd.
EA Pharma Co., Ltd.

AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion ofFully Human Anti-TNF-α Monoclonal Antibody HUMIRA®
in the Field of Gastrointestinal Disease

AbbVie GK (Headquarters: Tokyo, President: James C. Feliciano, “AbbVie”), Eisai Co., Ltd. (Headquarters:Tokyo, CEO: Haruo Naito, “Eisai”) and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO:Hajime Shimizu, “EA Pharma”), announced that EA Pharma and AbbVie will commence the co-promotionof fully human anti-TNF-α monoclonal antibody HUMIRA® for indications in the field of gastrointestinal
disease (ulcerative colitis, Crohn’s disease, intestinal Behçet’s disease) as of today.
Established in April 2016 through the integration of Eisai’s gastrointestinal disease business andAJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a fullvalue chain including research and development, production and logistics, sales and marketing. EAPharma has been delegated by Eisai to undertake co-promotion on gastrointestinal disease indications forHUMIRA with Abbvie.
Furthermore, there will be no change to the distribution and sales framework for HUMIRA (AbbVie is themarketing and manufacturing authorization holder for HUMIRA, while Eisai is responsible for distribution).
In addition, AbbVie and Eisai will continue co-promotion for HUMIRA of indications outside of thegastrointestinal disease field (treatment of rheumatoid arthritis [including prevention of structural joint
damage] and the following diseases that do not sufficiently respond to existing treatments: psoriasis
vulgaris, arthropathic psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis).
AbbVie, Eisai and EA Pharma will continue to promote and provide information on the proper use ofHUMIRA while making further contributions to improve the quality of life of patients.

[Notes to editors]
1．About HUMIRA

HUMIRA is a fully human anti-TNF-α monoclonal antibody which is approved for the following indications inJapan: “treatment of rheumatoid arthritis (including prevention of structural joint damage) and the following
diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris; arthropathic psoriasis;ankylosing spondylitis; polyarticular juvenile idiopathic arthritis; intestinal Behçet’s disease; moderate tosevere active Crohn’s disease as remission induction and maintenance therapy; and moderate to severe
ulcerative colitis.”
2．About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott
Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation todevelop and market advanced therapies that address some of the world’s most complex and serious diseases.
Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide andmarkets medicines in more than 170 countries. For further information on the company and its people, portfolio andcommitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn
page.
AbbVie GK was established in Japan in 2013. The company employs 900 people, dedicated to developing anddelivering treatments in our therapeutic areas focused on immunology, neonatology, liver disease and neuroscience,
where we believe we can make a remarkable impact on the lives of patients. For further information, please visit
www.abbvie.co.jp.
3．About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.
We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits
health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees
working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize
our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in ourstrategic areas of Oncology and Neurology.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com.
4. About EA Pharma
Established in April 2016 through the integration of Eisai’s gastrointestinal disease business and AJINOMOTOPHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including
research and development, production and logistics, sales and marketing.
For further information on EA Pharma Co., Ltd., please visit www.eapharma.co.jp.

Public Affairs
AbbVie GK
Tel: +81-(0)3-4577-1112

Media Inquiries
Public Relations Department
Eisai Co., Ltd.
Tel: +81-(0)3-3817-5120

Public Relations
EA Pharma Co., Ltd.
Tel: +81-(0)3-6280-9802